These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 37947466

  • 1. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
    Spoelstra SK, Visser L, Knegtering H.
    Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.
    Yohn SE, Conn PJ.
    Neuropharmacology; 2018 Jul 01; 136(Pt C):438-448. PubMed ID: 28893562
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
    Dean B, Scarr E.
    Psychiatry Res; 2020 Jun 01; 288():112989. PubMed ID: 32315882
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
    Martino G, Puma C, Yu XH, Gilbert AK, Coupal M, Markoglou N, McIntosh FS, Perkins MN, Laird JMA.
    Pain; 2011 Dec 01; 152(12):2852-2860. PubMed ID: 22018972
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
    Dean B.
    Expert Opin Investig Drugs; 2023 Dec 01; 32(12):1113-1121. PubMed ID: 37994870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.
    Montani C, Canella C, Schwarz AJ, Li J, Gilmour G, Galbusera A, Wafford K, Gutierrez-Barragan D, McCarthy A, Shaw D, Knitowski K, McKinzie D, Gozzi A, Felder C.
    Neuropsychopharmacology; 2021 May 01; 46(6):1194-1206. PubMed ID: 33342996
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Muscarinic acetylcholine M4 receptors play a critical role in oxotremorine-induced DARPP-32 phosphorylation at threonine 75 in isolated medium spiny neurons.
    Liu L, Huang Y, Huang Q, Zhao Z, Yu J, Wang L.
    Neuropharmacology; 2017 May 01; 117():376-386. PubMed ID: 28257887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S, Weiner I.
    Int J Neuropsychopharmacol; 2011 Oct 01; 14(9):1233-46. PubMed ID: 21211109
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.